AstraZeneca and Merck announced that the Phase III GY004 trial of cediranib in combination with Lynparza compared to platinum-based chemotherapy in platinum-sensitive relapsed ovarian cancer failed to meet the primary endpoint.

AstraZeneca Plc and Merck & Co. Inc.’s Lynparza won approval in China as a first-line treatment for a form of ovarian cancer.